Revenue Cycle Management Market worth $67.8 billion by 2026 - Exclusive Report by MarketsandMarkets™

 According to the new market research report "Revenue Cycle Management/RCM Market by Product & Services (Eligibility Verification, Clinical Coding, CDI, Claims Processing, Denial Management, Outsourcing Services, Cloud), End User(Payers, Hospitals, Outpatient), Covid-19 Impact - Global Forecast to 2026", published by MarketsandMarkets™, the global RCM Market is projected to reach USD 67.8 billion by 2026 from USD 40.9 billion in 2021, at a CAGR of 10.6% during the forecast period.

Browse in-depth TOC on "Revenue Cycle Management Market"

242 – Tables
40 – Figures
286 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153900104

The growth of this market is majorly attributed to the need for increasing patient volumes, and the growing need to manage unstructured healthcare data. Also, growing regulatory requirements & government initiatives are expected to drive demand growth in the IoT medical devices market during the forecast period.

By product & services, segment the outsourcing services segment is expected to grow at the highest growth rate during the forecast period

Among the product & services, the outsourcing services segment is expected to grow at the highest CAGR during the forecast period. The large share and high growth of this segment can be attributed to the lack of IT infrastructure and the shortage of skilled HCIT personnel.

By delivery mode, the on-premise segment is expected to account for the largest share of the revenue cycle management market

The on-premise segment accounted for the largest share of the global RCM Market in 2020. The large share of this segment is attributed to the increasing demand for mobile support systems for better customer (patient) engagement platforms.

By end user, the healthcare providers segment is expected to account for the largest share of the RCM Market

Based on end user, the revenue cycle management market is segmented into healthcare providers and healthcare payers. Revenue cycle management solutions help healthcare providers automate the process from patient registration to billing and claims processing and provide better transparency that improves the overall financial health of the provider organization. This is a major factor driving the growth of this segment.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=153900104

North America dominates the revenue cycle management market during the forecast period.

North America accounted for the largest share of the RCM Market in 2020. The large share of this region can be attributed to factors such as stringent regulations, increasing volume of claims denials, the presence of a high number of private healthcare payers and well-established government payers, and a large number of healthcare IT companies are some of the factors driving the growth of the revenue cycle management market in this region.

R1 RCM (US), Cerner Corporation (US), Optum (US) are the leading players in the market. Other players include McKesson Corporation (US), Change Healthcare (US), 3M (US), Experian plc (Ireland), Conifer Health Solutions (US), Allscripts Healthcare Solutions (US), GE Healthcare (US), Cognizant (US), athenahealth (US), SSI Group LLC (US), AdvantEdge Healthcare (US), and Huron Consulting Group (US)

Nerve Repair and Regeneration Market worth $11.6 billion by 2027 - Exclusive Report by MarketsandMarkets™

 "Nerve Repair and Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2027", published by MarketsandMarkets™, the global Nerve Repair Market is projected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, growing at a CAGR of 12.1% from 2022 to 2027.

Browse in-depth TOC on "Nerve Repair Market and Nerve Regeneration Market"
313 – Tables
42 – Figures
236 – Pages

Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883

The Growth in this Nerve Repair Market can be attributed to the massive geriatric population, increasing research investments on the neurological disorders, high volume of nerve injury cases, and the high prevalence of neurological diseases.

In 2021, Neurostimulation and Neuromodulation Devices accounted for the largest share of the nerve regeneration market, by product.

By product, the nerve repair & regeneration market is segmented into neurostimulation and neuromodulation devices and biomaterials. The neurostimulation and neuromodulation devices segment is estimated to grow at the highest growth rate during the forecast period with the increasing government investments for neurologic disorders studies, and the favourable reimbursement.

By neurostimulation and neuromodulation application, internal neurostimulation and neuromodulation accounted for the largest market share in 2021.

Based on the neurostimulation and neuromodulation application, the nerve repair and regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation neuromodulation segment is expected to hold the largest share and is expected to register the highest CAGR during the forecast period. The largest share and high growth rate are driven by the increasing incidence of neurological disorders across the globe is driving the growth of this segment.

By Biomaterials application, direct nerve repair/neurorrhaphy accounted for the largest market share in 2021.

Based on application, the nerve repair & regeneration market is segmented into direct nerve repair/neurorrhaphy, nerve grafting, and stem cell therapy. In 2021, the direct nerve repair segment accounted for the largest share of the market. This can be attributed to the increasing incidence of neurological disorders across the globe.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=883

North America was the largest regional market for nerve repair & regeneration market in 2021.

The nerve repair market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Rest of the World (Latin America, and Middle East & Africa). North America held the largest share of the nerve regeneration market in 2021, followed by Europe. The largest market share of North America is driven by the high incidence of strong presence of industry players, neurological disorders, and favourable reimbursement policies in the region.

Some of the major players operating in the global nerve repair market include Medtronic, plc. (Ireland), Boston Scientific Corporation (US), and Abbott Laboratories (US). The other players operating in the market are Axogen Corporation (US), Baxter (US), LivaNova PLC (UK), Integra LifeSciences (US), Neuronetics Inc. (US), Nevro Corp (US), NeuroPace Inc. (US), Polyganics (Netherlands), Soterix Medical Inc (US), Synapse Biomedical Inc. (US), Aleva Neurotherapeutics SA (Switzerland), Collagen Matrix Inc. (US), KeriMedical (Switzerland), BioWaveGO USA (US), NeuroSigma Inc. (US), tVNS Technologies GmbH (Germany), GiMer Medical (Taiwan), Checkpoint Surgical Inc. (US), Renishaw PLC (UK), Alafair Biosciences, Inc. (US), electroCore, Inc. (US), BlueWind Medical (Israel), Helius Medical Technologies (US), and BioControl Medical (Israel).

High-Throughput Screening Market worth $26.4 billion by 2025 - Exclusive Report by MarketsandMarkets™

 The high-throughput screening (HTS) market growth is driven mainly by factors such as increasing R&D spending by pharmaceutical & biotechnology companies, technological advancements in high-throughput screening market and the availability of government funding & venture capital investments. Emerging markets and growing applications in life sciences research are also factors expected to provide growth opportunities for players in the market.

The global high-throughput screening (HTS) market size is projected to reach USD 26.4 billion by 2025 from USD 15.3 billion in 2020, at a CAGR of 11.5% during the forecast period.

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134981950

Scope of the Report

This report categorizes the high-throughput screening market into the following segments and subsegments:

High-throughput screening Market, by Product & Service

• Consumables
• Reagents & Assay Kits
• ;Laboratory Equipment
• Instruments
• Liquid Handling Systems
• Detection Systems
• Other Instruments
• Services
• Software

High-throughput Screening Market, by Technology

• Cell-based Assays
•  2D Cell Culture
• 3D Cell Culture
• Scaffold-based Technology
• Hydrogels
• Animal-derived Hydrogels
• Matrigel
• Collagen
• Synthetic Hydrogels
• Alginate/Agarose
• Inert Matrix/Solid Scaffolds
• Micropatterned Surfaces
• Scaffold-free Technology
• Ultra-low Binding Plates   
• Hanging-drop Plates
• Other Scaffold-free Technologies
• Reporter-based Assays
• Perfusion Cell Culture
• Lab-on-a-Chip Technology (LOC)
• Label-free Technology

High-throughput Screening Market, by Application

• Drug Discovery
• Biochemical Screening
• Life Sciences Research
• Other Applications

High-throughput Screning Market, by End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Other End Users

High-throughput Screning Market, by Region

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe (RoE)
• Asia Pacific (APAC)
• Japan
• China
• India
• Australia
• Rest of Asia Pacific (RoAPAC)
• Rest of the World (RoW)
• Latin America
• Middle East and Africa

Market Segmentation:

On the basis type of product & service, the HTS Market is broadly segmented into consumables , instruments, services, and software. In 2019, consumables accounted for the largest share of the high-throughput screening (HTS) market. This can primarily be attributed to the wide use of reagents & assay kits in HTS techniques, increasing pharmaceutical R&D, and rising government funding for life sciences research.

Based on application, the HTS Market is categorized into four segments—drug discovery, biochemical screening, life sciences, and other applications. The drug discovery application segment accounted for the largest share of the market in 2019. The key factor driving this segments growth is the increasing number of clinical trials and rising pharmaceutical R&D expenditure.

Regional Analysis:

In 2019, Asia Pacific region accounted for the fastest-growing region of the HTS Market. It is also estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the market in this region.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=134981950

Top Key Players:-

Some of the prominent players in the high-throughput screening market are Thermo Fisher Scientific Inc. (US),  Agilent Technologies, Inc. (US), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Group Ltd. (Switzerland), AXXAM S.p.A. (Italy), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Corning Incorporated (US), and Eurofins Scientific (Luxembourg).

 

 

Koninklijke Philips N.V. and ResMed are the Prominent Players in the Ventilators Market

 A ventilator, breathing machine, or respirator is a machine that assists with breathing. It is mainly used in hospitals to treat chronic obstructive pulmonary disease (COPD), sleep apnea, acute lung injury, and hypoxemia. Over the years, the ventilators market has evolved significantly due to technological advancements, such as developing advanced portable ventilators and improvements in the sensor technologies used in ventilators. The increasing number of preterm births, rapid growth in the geriatric population, rising prevalence of respiratory diseases, rising number of ICU beds, and rising number of COVID-19 patients are expected to drive growth in the ventilators market during the forecast period. The emergence of home healthcare has opened new avenues for the ventilators market. Convenience and comfort in the home care environment, coupled with cost advantages, are the other major factors driving growth in the home healthcare market for ventilators.

The Ventilators market is projected to reach USD 1.9 billion in 2026 from USD 1.4 billion in 2021, at a CAGR of 7.6% during the forecast period.

 

To know about the assumptions considered for the study download the pdf brochure

 

The global ventilators market are Koninklijke Philips N.V. (Netherlands), ResMed (US), Medtronic (Ireland), Fisher & Paykel Healthcare Limited (New Zealand), Drägerwerk AG & CO. KGAA (Germany), Nihon Kohden Corporation (Japan), Getinge AB (Sweden), Asahi Kasei Corporation (Japan), Air Liquide (France), Vyaire Medical, Inc. (US), GE Healthcare (US), Hamilton Medical (Switzerland), Smiths Group plc (UK), Allied Healthcare Products, Inc. (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd, (China), aXcent Medical GmbH (Germany), Metran Co., Ltd (Japan), MAGNAMED (Brazil), Avasarala Technologies Ltd (India), Airon Corporation (Florida), TRITON Electronic Systems Ltd. (Russia), Bio-Med Devices, Inc. (US), Hill-Rom Holdings, Inc. (US), HEYER Medical AG (Germany), and Leistung Engineering Pvt. Ltd. (Argentina). These companies adopted strategies such as acquisitions, partnerships, expansions, and product launches to enhance their presence in the ventilators market.

Koninklijke Philips N.V. is a leading provider of medical tools for different healthcare specialties. Philips Respironics, a subsidiary of Philips Healthcare, primarily focuses on providing respiratory care devices. Philips Healthcare has a significant global footprint owing to its strong sales and distribution network. It significantly invests in R&D activities to add innovative technologies and products to its portfolio, which has helped it strengthen its presence in the market. For instance, the R&D expenditure increased from USD 2.11 billion in 2019 to USD 2.19 billion in 2020. The company also has made significant acquisitions to expand its presence in the ventilators market. For instance, the company’s growth has been fueled by strategic partnerships and collaborations with various companies and organizations such as SinoMed Imaging System, InSightec, the Yale School of Medicine (US), and Hologic, Inc. (US). In addition, it has strengthened its ventilator customer base by collaborating with the US government. This collaboration has helped increase hospital ventilators production in Philip’s manufacturing sites in the US to combat the COVID-19 pandemic.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=11018337

ResMed provides a broad portfolio of ventilators products and has a wide geographic presence across North America, the Asia Pacific, and Europe. ResMed is well-positioned in the ventilators market and focuses on developing new and innovative products. In accordance with this, over the last five years, the company developed and launched several respiratory care products; for instance, in August 2018, ResMed enhanced its Astral life support ventilators, including Optional AutoEPAP in iVAPS for the US patients, a high-demand therapy option. The company is also engaged in enhancing its geographical presence in high-growth regions by acquiring regional companies. For example, in March 2019, ResMed acquired HB Healthcare Safety (South Korea), a home-based medical equipment provider for sleep and respiratory care devices like ventilators.

 

Urology Devices Market: Rising incidence and prevalence of urological conditions

 Over the last few decades, the incidence and prevalence of urological conditions, such as chronic kidney disease (CKD), end-stage renal disease (ESRD), urinary incontinence, kidney and ureteral stones, and bladder and prostate cancer, have increased significantly across the globe. According to the Global Forum on Incontinence, 4−8% of the global population (approximately 400 million people) were affected by urinary incontinence in 2018. Urology-related consumables such as urinary catheters are used to manage incontinence, which cannot be treated or managed with medicines or surgery. The prevalence of urinary incontinence is expected to grow due to the growing aging population and the increasing incidence of obesity, as these are the two major risk factors for urinary incontinence. This is expected to fuel the market growth.

The global urology devices market is projected to reach USD 46.4 billion by 2026 from USD 38.0 billion in 2021, at a CAGR of 4.1%.

Download PDF Brochure: -  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173062212

Market Segmentation:

The urology devices market is segmented into kidney diseases, urological cancer and BPH, pelvic organ prolapse, and other applications based on application. In 2020, the urological cancer and BPH segment accounted for the highest growth rate. This can be attributed to the rising incidence of urological cancers coupled with the growing number of cancer-related surgeries.

Based on product, the market is segmented into instruments and consumables & accessories. The instruments segment accounted for the largest share of the market in 2020. This segment includes dialysis devices, endoscopes, laser and lithotripsy devices, robotic systems, endovision and imaging systems, insufflators, endoscopy fluid management systems, and urodynamic systems.

Based on end users, the market is segmented into hospitals, ASCs, and clinics; dialysis centers; and home care settings. In 2020, the hospitals, ASCs, and clinics segment accounted for the largest share of the market. The improving healthcare infrastructure in developing countries such as India, the rising number of target procedures, and the rising number of surgeries are the major factors driving this segments growth.

Regional Analysis:

The Urology Devices market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the urology devices market.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=173062212

Top Key Players:-

The major players operating in this urology devices market are  Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), Olympus Corporation (Japan), B. Braun Melsungen AG (Germany), Stryker Corporation (US), KARL STORZ (Germany), Cook Medical (US), Intuitive Surgical (US), Medtronic plc (Ireland), Cardinal Health (US), Teleflex Incorporated (US), Richard Wolf GmbH (Germany), CompactCath (US), Dornier MedTech (Germany), Nikkiso Co., Ltd. (Japan), Balton Sp. z o.o. (Poland), Dialife SA (Switzerland), Maxer Endoscopy GmbH (Germany), Vimex Sp. z o.o. (Poland), Amsino International, Inc. (US), ROCAMED (Monaco), Well Lead Medical Co., Ltd. (China), Medispec (US), Medical Technologies of Georgia (Georgia), EndoMed Systems GmbH (Germany), Hunter Urology (England), J and M Urinary Catheters LLC (US), and Ribbel International Limited (India).

Molecular Quality Controls Market: Increasing number of accredited clinical laboratories

 The growth of Molecular Quality Controls Market is primarily driven by factors such as the rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines and declining costs of sequencing procedures and increasing prevalence of infectious diseases, cancer & genetic diseases.

The molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD 226 million by 2026, at a CAGR of 6.7% during the forecast period. 

Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523

Market Segmentation:

Based on product, the molecular quality control market is segmented into Independent Controls and Instrument Specific Controls. The Independent control segment accounted for the largest share of the market in 2020. The increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results are driving the growth of the molecular quality control products market.

Based on analyte type, the market is segmented into single-analyte controls and multi-analyte controls. Single-analyte controls dominated the molecular quality controls market in 2020 due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.

Based on application, the molecular quality control market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The infectious disease diagnostics segment accounted for the largest share of the molecular quality controls market in 2020. The large share of this segment is attributed to the development of advanced assays for infectious diseases, a significant increase in the prevalence of infectious diseases, and the rising awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

The key end users of molecular quality controls studied in this report include diagnostic laboratories, hospitals, IVD Manufacturers and CROs Academic & Research Institutes, and other end users. The Diagnostic Laboratories segment accounted for the largest share of the market in 2020, increasing number of accredited diagnostic laboratories to provide growth opportunities in the coming years.

Regional Analysis:

The molecular quality control market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America was the largest regional market for molecular quality controls due to the developed healthcare system in the US and Canada, the presence of many leading molecular quality control product manufacturers in the region, and the easy accessibility to technologically advanced products in the region.

Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523

Top Key Players:

The prominent players in the molecular quality controls market are F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US), Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).